Valneva Stock Down 2.63% Midday After Yesterday's Surge

Current Market Dynamics and Technical Indicators

On Wednesday, January 7th, Valneva's stock recorded a midday decline of 2.63% to €4.0800, following a sharp rise of nearly 8% the previous day due to a favorable recommendation from Stifel. Trading volumes remained moderate with 0.39% of capital traded during the session, indicating a typical profit-taking following a sudden upward movement. Over a week, however, the performance remains positive with a 9.38% increase, showing a resurgence of investor interest in this Franco-Austrian biotechnology company. Over three months, the stock has declined by 16.22%, reflecting ongoing uncertainties around the IXCHIQ chikungunya vaccine, whose license was suspended by the US FDA in November. However, the annual performance remains impressive with a surge of 78.48%, driven by advancements in the VLA15 Lyme disease program developed in partnership with Pfizer. From a technical perspective, the stock is currently trading above its 50-day moving average of €3.82, confirming a positive short-term dynamic. The RSI at 69 is approaching the overbought zone at 70, suggesting a legitimate technical pause after the previous day's progress. The MACD indicator shows a positive setup with a line at 0.02 and a signal line at -0.03, indicating that the bullish momentum is still intact despite today's decline.

Stifel's Optimistic Outlook and Market Potential

On Monday, January 6th, the American investment bank Stifel reiterated its buy recommendation on Valneva while raising its price target to €10, representing a potential upside of 145% from the current price. The analyst is particularly optimistic ahead of the Phase 3 results for VLA15, a vaccine developed in partnership with Pfizer against Lyme disease, expected in the first half of 2026. Stifel believes that an efficacy of 70% to 80% would be perceived as a positive result and sees about 200% upside potential in its base scenario if the study is successful. VLA15 is currently the only advanced clinical candidate vaccine against Lyme disease, a bacterial pathology transmitted by ticks affecting approximately 476,000 people annually in the United States and 130,000 in Europe. Given the significant unmet medical needs and the increasing prevalence of Lyme disease, the analyst estimates that the maximum annual sales of the vaccine could reach €1.9 billion. If the results are positive, Pfizer is expected to file for marketing authorization in the second half of 2026, with potential approval in 2027 and a commercial launch targeted for the end of 2027. This prospect explains the recent enthusiasm of investors anticipating a major catalyst that could unlock significant valuation for the laboratory. The technical support identified at €3.49 has been tested several times in recent weeks and appears to hold firmly, while the major resistance is at €4.30, a level that will be a key threshold to cross for a sustained recovery.

Strategic Shifts and Financial Outlook

On December 31st, 2025, the Franco-Austrian laboratory announced the end of its licensing agreement with the Serum Institute of India concerning IXCHIQ, its vaccine against chikungunya. The strategic goal of this rights reacquisition is to assume direct control of the supply chain and marketing in endemic countries where the disease risk is high. This decision is part of the financing agreement signed with the Coalition for Epidemic Preparedness Innovations, co-funded by the European Union, aimed at accelerating access to the vaccine in the most affected regions. This move comes in a context marked by the FDA's suspension in November of IXCHIQ's license for the traveler's market, a decision that led the company to revise its annual sales targets downward. For the first nine months of 2025, Valneva reported revenue of €127 million, up 8.9% compared to the same period last year. Annual sales are now expected to be between €155 and €170 million, down from an initial range of €170 to €180 million. The adjusted EBITDA remains negative at -€37.7 million over nine months, reflecting sustained investments in research and development estimated between €80 and €90 million for the full year. Valneva has a cash reserve of €143 million at the end of the third quarter of 2025, which Stifel believes provides a sufficient financing horizon until the planned launch of VLA15 in 2027. The one-month volatility stands at 13.61%, characteristic of biotechnology values awaiting major catalysts, before the decisive results expected in the first half of 2026 for the Lyme disease vaccine.